Trametinib is a MEK1/2 inhibitor approved by the FDA in combination with dabrafenib for unresectable or metastatic melanoma and non–small-cell lung cancer carrying mutations in BRAF (V600E/V600K). Here, MAP2K1 is linked to lung cancer.